OraSure Technologies, Inc. (NASDAQ: OSUR)
OraSure Technologies, Inc. (OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its 2015 second quarter financial results.
OraSure Earnings and Outlook
Consolidated net revenues for the second quarter of 2015 were a record $30.4 million, a 15% increase from the comparable quarter of 2014.
The Company’s molecular collection systems subsidiary, DNA Genotek (“DNAG”), contributed $8.1 million in net revenues during the second quarter of 2015, which is a record and represents a 65% increase over the second quarter of 2014.
Net domestic product revenues for the Company’s OraQuick® rapid HCV test were $1.7 million for the second quarter of 2015, representing a 39% increase over the second quarter of 2014. GlobeNewsWire
OraSure CEO’s Comments
“We are pleased with the record level of revenues reported for the second quarter of 2015 as well as our bottom line results,” said Douglas A. Michels, President and CEO of OraSure Technologies. “Our molecular collection systems business continues the high performance level we have seen in recent quarters and our HCV business continues to grow nicely. We are also making good progress in our efforts to fund and commercialize a rapid Ebola test on our OraQuick® platform. With the first half of the year now complete, I believe we are well positioned to deliver solid growth and full year profitability for 2015.” GlobeNewswire
OSUR Technical Analysis
OSUR gapped up in price today to $5.11 up from yesterday’s close of $5.02 which is a 2% increase in price based on positive earnings release. Taking a look at the daily chart we can see some consolidation at the $5.40 price level that was reached on June 14 and June 17. Taking a further look back we can see a high reached on June 19 of $6 which could be used as a resistance level. For trading purposes I would use an entry price of $5.20 with a possible add on at $5.40 looking for a run to $6.00. My stop price would be $5.10 which is pretty tight but right at the gap up price. Since the gap up was only 2% today my stop is a little tighter than usual.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepITMAX, OMNIgeneGut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania. Yahoo Finance